Perioperative bridging of chronic oral anticoagulation in patients undergoing pacemaker implantation-a study in 200 patients

Europace

Volumn 13, Issue 9, 2011, Pages 1304-1310

  Hammerstingl, Christoph ^a   Omran, Heyder ^b  

^a UNIVERSITY HOSPITAL BONN   (Germany)

^b ST MARIEN HOSPITAL   (Germany)

Author keywords

Bridging therapy; Low molecular weight heparin; Oral anticoagulation; Pacemaker implantation; Risk stratification

Indexed keywords

ANTICOAGULANT AGENT; ANTIVITAMIN K; ENOXAPARIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN;

ADULT; ADVERSE OUTCOME; AGED; ANTICOAGULATION; ARTICLE; ARTIFICIAL HEART PACEMAKER; BLEEDING; BRIDGING THERAPY; CLINICAL PRACTICE; CONFIDENCE INTERVAL; CONGESTIVE HEART FAILURE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HAZARD RATIO; HEART TAMPONADE; HEART VENTRICLE PACING; HEMATOMA; HUMAN; IMPLANTATION; INTERNATIONAL NORMALIZED RATIO; KIDNEY FUNCTION; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; OPEN HEART SURGERY; OUTPATIENT CARE; PERICARDIAL EFFUSION; PERIOPERATIVE PERIOD; PRACTICE GUIDELINE; PREDICTION; PREVALENCE; PRIORITY JOURNAL; REGISTER; REGRESSION ANALYSIS; REOPERATION; RISK ASSESSMENT; THROMBOCYTOPENIA; THROMBOEMBOLISM; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; ANTICOAGULANTS; CARDIAC SURGICAL PROCEDURES; ENOXAPARIN; FEMALE; HEART FAILURE; HEMORRHAGE; HUMANS; MALE; PACEMAKER, ARTIFICIAL; PERIOPERATIVE PERIOD; POSTOPERATIVE COMPLICATIONS; PREVALENCE; RENAL INSUFFICIENCY; RISK; THROMBOCYTOPENIA; THROMBOEMBOLISM;

EID: 80052243563     PISSN: 10995129     EISSN: 15322092     Source Type: Journal    
DOI: 10.1093/europace/eur107     Document Type: Article

References (33)

1. McComb JM, Gribbin GM. Chronic atrial fibrillation in patients with paroxysmal atrial fibrillation, atrioventricular node ablation and pacemakers: Determinants and treatment. Europace 1999;1:30-4.
2. Douketis JD, Berger PB, Dunn AS, Jaffer AK, Spyropoulos AC, Becker RC, Ansell J. The perioperative management of antithrombotic therapy: American college of chest physicians evidence-based clinical practice guidelines (8th Edition). Chest, 2008;133(6suppl):299S-339.
3. Fuster V, Ryden LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, Halperin JL, Le Heuzey JY, Kay GN, Lowe JE, Olsson SB, Prystowsky EN, Tamargo JL,Wann S, Smith SC Jr, Jacobs AK, Adams CD, Anderson JL, Antman EM, Halperin JL, Hunt SA, Nishimura R, Ornato JP, Page RL, Riegel B, Priori SG, Blanc JJ, Budaj A, Camm AJ, Dean V, Deckers JW, Despres C, Dickstein K, Lekakis J, McGregor K, Metra M, Morais J, Osterspey A, Tamargo JL, Zamorano JL. ACC/ AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: Full text: A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 guidelines for the management of patients with atrial fibrillation) developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Europace 2006;8:651-745.
4. Salem DN, Stein PD, Al-Ahmad A, Bussey HI, Horstkotte D, Miller N, Pauker SG. Antithrombotic therapy in valvular heart disease-native and prosthetic: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest, 2004;126(3 Suppl):457S-82S. (Pubitemid 39297961)
5. Daubert JC, Mabo P. Continue or withhold oral anticoagulation in high-risk patients undergoing pacemaker or ICD implantation. Eur Heart J, 2009 August 28.
6. Robinson M, Healey JS, Eikelboom J, Schulman S, Morillo CA, Nair GM, Baranchuk A, Ribas S, Evans G, Connolly SJ, Turpie AG. Postoperative low-molecular-weight heparin bridging is associated with an increase in wound hematoma following surgery for pacemakers and implantable defibrillators. Pacing Clin Electrophysiol 2009;32:378-82.
7. Wiegand UK, LeJeune D, Boguschewski F, Bonnemeier H, Eberhardt F, Schunkert H, Bode F. Pocket hematoma after pacemaker or implantable cardioverter defibrillator surgery: Influence of patient morbidity, operation strategy, and perioperative antiplatelet/anticoagulation therapy. Chest 2004;126:1177-86. (Pubitemid 39391248)
8. Marquie C, De GG, Klug D, Kouakam C, Brigadeau F, Jabourek O, Trillot N, Lacroix D, Kacet S. Post-operative use of heparin increases morbidity of pacemaker implantation. Europace 2006;8:283-7. (Pubitemid 43905736)
9. Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G. Pharmacology and Management of the Vitamin K Antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest, 2008; 133(6suppl):160S-198S.
10. Klug D, Balde M, Pavin D, Hidden-Lucet F, Clementy J, Sadoul N, Rey JL, Lande G, Lazarus A, Victor J, Barnay C, Grandbastien B, Kacet S. Risk factors related to infections of implanted pacemakers and cardioverter-defibrillators: Results of a large prospective study. Circulation 2007;116:1349-55. (Pubitemid 47417560)
11. Jamula E, Douketis JD, Schulman S. Perioperative anticoagulation in patients having implantation of a cardiac pacemaker or defibrillator: A systematic review and practical management guide. J Thromb Haemost 2008;6:1615-21.
12. Hammerstingl C, Tripp C, Schmidt H, von der RG, Omran H. Periprocedural bridging therapy with low-molecular-weight heparin in chronically anticoagulated patients with prosthetic mechanical heart valves: Experience in 116 patients from the prospective BRAVE registry. J Heart Valve Dis 2007;16:285-92. (Pubitemid 46887057)
13. Omran H, Hammerstingl C, Paar WD. Perioperative Bridging with Enoxaparin. Results of the Prospective BRAVE Registry with 779 Patients. Med Klin (Munich) 2007;102:809-15. (Pubitemid 47628409)
14. Federal Institute for Medicinal Products and Medical Devices. German Drug Law (Arzneimittelgesetz - AMG) of the Federal Republic of Germany. http://www.bfarm. de/cln-030/nn-891668/SharedDocs/Publikationen/EN/BfArM/ service/AMG-en, templateId=raw,property=publicationFile.pdf/AMG-en.pdf. Accessed on 9. February 2009. 9. Ref Type: Generic.
15. Douketis JD, Crowther MA, Cherian SS, Kearon CB. Physician preferences for perioperative anticoagulation in patients with a mechanical heart valve who are undergoing elective noncardiac surgery. Chest 1999;116:1240-6. (Pubitemid 29535974)
16. Garcia DA, Regan S, Henault LE, Upadhyay A, Baker J, Othman M, Hylek EM. Risk of thromboembolism with short-term interruption of warfarin therapy. Arch Intern Med 2008;168:63-9.
17. Kovacs MJ, Kearon C, Rodger M, Anderson DR, Turpie AG, Bates SM, Desjardins L, Douketis J, Kahn SR, Solymoss S,Wells PS. Single-arm study of bridging therapy with low-molecular-weight heparin for patients at risk of arterial embolism who require temporary interruption of warfarin. Circulation 2004;110: 1658-63. (Pubitemid 39297990)
18. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31-41.
19. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. The GUSTO investigators. N Engl J Med 1993;329: 673-82.
20. Chesebro JH, Knatterud G, Roberts R, Borer J, Cohen LS, Dalen J, Dodge HT, Francis CK, Hillis D, Ludbrook P. Thrombolysis in Myocardial Infarction (TIMI) Trial, Phase I: A comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge. Circulation 1987;76:142-54. (Pubitemid 17093202)
21. Camm AJ, Kirchhof P, Lip GY, Schotten U, Savelieva I, Ernst S, Van GI, Al-Attar N, Hindricks G, Prendergast B, Heidbuchel H, Alfieri O, Angelini A, Atar D, Colonna P, De CR, De SJ, Goette A, Gorenek B, Heldal M, Hohloser SH, Kolh P, Le Heuzey JY, Ponikowski P, Rutten FH. Guidelines for the management of atrial fibrillation: The task force for the management of atrial fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010;31:2369-429.
22. Douketis JD, Woods K, Foster GA, Crowther MA. Bridging anticoagulation with low-molecular-weight heparin after interruption of warfarin therapy is associated with a residual anticoagulant effect prior to surgery. Thromb Haemost 2005;94: 528-31.
23. Hoffmeister HM, Bode C, Darius H, Huber K, Rybak K, Silber S. Positionspapier Unterbrechung antithrombotischer Behandlung (Bridging) bei kardialen Erkrankungen. Der Kardiologe 2010;4:365-374. Ref Type: Journal (Full)
24. Vahanian A, Baumgartner H, Bax J, Butchart E, Dion R, Filippatos G, Flachskampf F, Hall R, Iung B, Kasprzak J, Nataf P, Tornos P, Torracca L, Wenink A. Guidelines on the management of valvular heart disease: The Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology. Eur Heart J 2007;28:230-68. (Pubitemid 46276943)
25. Michaud GF, Pelosi F Jr, Noble MD, Knight BP, Morady F, Strickberger SA. A randomized trial comparing heparin initiation 6 h or 24 h after pacemaker or defibrillator implantation. J Am Coll Cardiol 2000;35:1915-8. (Pubitemid 30342875)
26. Tolosana JM, Berne P, Mont L, Heras M, Berruezo A, Monteagudo J, Tamborero D, Benito B, Brugada J. Preparation for pacemaker or implantable cardiac defibrillator implants in patients with high risk of thrombo-embolic events: Oral anticoagulation or bridging with intravenous heparin? A prospective randomized trial. Eur Heart J 2009;30:1880-4.
27. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: Results from the National Registry of Atrial Fibrillation. JAMA 2001;285:2864-70. (Pubitemid 32537350)
28. Levine MN, Raskob G, Beyth RJ, Kearon C, Schulman S. Hemorrhagic complications of anticoagulant treatment: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126(3 Suppl):287S-310S. (Pubitemid 39297958)
29. Vahanian A. Antithrombotic therapy for patients with valvular heart disease. Herz 2008;33:44-51. (Pubitemid 351276885)
30. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation: A major contributor to stroke in the elderly. The Framingham Study. Arch Intern Med 1987;147:1561-4. (Pubitemid 17138836)
31. Hirsh J, Warkentin TE, Shaughnessy SG, Anand SS, Halperin JL, Raschke R, Granger C, Ohman EM, Dalen JE. Heparin and low-molecular-weight heparin: Mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest 2001;119(1 Suppl):64S-94S. (Pubitemid 32154195)
32. Berkowitz SD, Stinnett S, Cohen M, Fromell GJ, Bigonzi F. Prospective comparison of hemorrhagic complications after treatment with enoxaparin versus unfractionated heparin for unstable angina pectoris or non-ST-segment elevation acute myocardial infarction. Am J Cardiol 2001;88:1230-4. (Pubitemid 33132089)
33. Hulot JS, Montalescot G, Lechat P, Collet JP, Ankri A, Urien S. Dosing strategy in patients with renal failure receiving enoxaparin for the treatment of non-ST-segment elevation acute coronary syndrome. Clin Pharmacol Ther 2005; 77:542-52. (Pubitemid 40824967)